Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1811 Combinations in Neoadjuvant HER2+ Breast Cancer
NCT06927180Phase 2Recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Apr 2025
- Primary completion
- May 2029
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of trastuzumab rezetecan in breast cancer (3 arms), sponsored by Henan Cancer Hospital. Primary endpoint: Pathological Complete Response Rate. Started Apr 2025; status: recruiting.
02
Drugs
trastuzumab rezetecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06927180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06927180.